YOLFTbeta
06

SunBio,Inc.

067370 · KQ · Healthcare / Biotechnology

5,060.00KRW+60.00 (+1.20%)

Price History

Full chart

Market Stats

Previous Close5,000.00
Open5,400.00
Day Range4,990.00 – 5,400.00
52-Week Range4,840.00 – 8,500.00
Volume2.61K
Market Cap66.90B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.65
50-Day Avg6,103.40
200-Day Avg6,010.05

About

SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage. The company offers MucoPEG, a medical device for treatment of dry mouth syndrome; and SynoGEL, a viscosupplement for arthritic Knee. Its preclinical stage biopharmaceuticals candidates target brain stroke and chronic anemia. It also manufactures and sells PEG derivatives. The company was founded in 1997 and is headquartered in Gunpo-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • Headquarters95, Sanbon-ro, Gunpo-si, South Korea, 15849, Korea
  • Websitehttps://www.sunbio.com

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue7.42B12.29B8.68B13.67B
Growth (%)-+65.65%-29.36%+57.47%
Cost of Revenue2.91B3.66B2.76B5.33B
Gross Profit4.51B8.64B5.92B8.34B
Gross Margin60.83%70.26%68.19%61.00%
Operating Expense4.32B3.44B6.45B3.30B
Operating Income190.91M5.19B-533.24M5.04B
Operating Margin2.57%42.24%-6.14%36.83%
EBITDA1.82B6.52B1.58B5.93B
EBITDA Margin24.58%53.05%18.17%43.34%
Net Income869.33M4.61B-104.38M2.79B
Net Income Margin11.72%37.48%-1.20%20.43%
R&D1.27B1.36B4.41B1.27B
R&D as % of Total Revenue17.05%11.06%50.78%9.29%
Interest Expense83.39M31.41M485.25M1.25B
Interest Expense % of Total Revenue1.12%0.26%5.59%9.14%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets42.90B47.66B61.02B60.68B
Total Liabilities19.06B19.56B33.94B31.81B
Total Equity23.84B28.11B27.08B28.87B
Cash1.10B5.75B6.19B2.75B
Net Debt15.90B10.25B23.88B25.66B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.64B4.97B1.17B3.82B
Capital Expenditure18.79B8.61B15.87B3.24B
Free Cash Flow-17.15B-3.64B-14.70B576.63M
Dividends Paid-615.27M922.90M-
FCF to OCF-1045.83%-73.27%-1253.09%15.11%
Dividend Paid to FCF--16.90%-6.28%-

Earnings

Report DateDec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------
EPS Actual-67.234.61203.56177.34-11.18-30.46-66.54-38.14126.6550.06-97.07104.84171.7126.1751.87
Surprise---------------
Timing---------------

Key Statistics & Ratios

Market Cap66.90B
Enterprise Value94.16B
Trailing P/E0.00
Forward P/E0.00
Price / Sales30.82
Price / Book2.29
Revenue (TTM)2.17B
Gross Profit (TTM)1.23B
EBITDA403.98M
Profit Margin64.22%
Operating Margin16.09%
Return on Equity35.40%
Return on Assets4.64%
Shares Outstanding12.19M
Shares Float3.51M
Beta0.65
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
75.00Dec 27, 2024
20231×
75.00Dec 27, 2023
20221×
50.00Dec 28, 2022

Stock Splits

  • Jan 7, 20211.5:1